R&D Pipeline

FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), anemia in myelodysplastic syndromes (MDS) and chemotherapy induced anemia (CIA), idiopathic pulmonary fibrosis (IPF), Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer. The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.

HIF Platform

Preclinical

Phase 1

Phase 2

Phase 3

Approved

HIF Platform Phases

United States

ROXADUSTAT (HIF-PHI) ANEMIA OF CKD

CRL Received

China

Approved

Europe

Approved

Japan

Approved

1

FDA issued a complete response letter on 8/10/21

1

Roxadustat Anemia in MDS Chart

ROXADUSTAT (HIF-PHI) ANEMIA IN MDS

 

United States

 

China

Phase 3

Phase 3

Roxadustat Anemia in CIA Chart

United States

Phase 2

ROXADUSTAT (HIF-PHI) ANEMIA IN CIA

Fibrotic Disease Platform

Preclinical

Phase 1

Phase 2

Approved

Phase 3

Pamrevlumab chart

Locally Advanced Pancreatic Cancer

Idiopathic Pulmonary Fibrosis

Duchenne Muscular Dystrophy

PAMREVLUMAB
(ANTI-CTGF ANTIBODY)

Phase 3

Phase 3

Phase 3

PARTNERED

WHOLLY-OWNED

Roxadustat

Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin.

Pamrevlumab

Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.

Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.